{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T12:49:30Z","timestamp":1783601370166,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s00417-021-05169-1","type":"journal-article","created":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T15:20:11Z","timestamp":1618500011000},"page":"2949-2959","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Topical ketorolac as an adjunctive treatment with intravitreal bevacizumab in the management of diabetic macular edema: A double-masked placebo-controlled randomized clinical trial"],"prefix":"10.1007","volume":"259","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2414-4661","authenticated-orcid":false,"given":"Homayoun","family":"Nikkhah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Niazpour Moez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morteza","family":"Entezari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Ramezani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiana","family":"Hassanpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Karimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Yaseri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,15]]},"reference":[{"key":"5169_CR1","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/S0140-6736(09)62124-3","volume":"376","author":"N Cheung","year":"2010","unstructured":"Cheung N, Mitchell P, Wong TY (2010) Diabetic retinopathy. Lancet 376:124\u2013136","journal-title":"Lancet"},{"key":"5169_CR2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.ophtha.2008.10.016","volume":"116","author":"R Klein","year":"2009","unstructured":"Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE (2009) The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology 116:497\u2013503. https:\/\/doi.org\/10.1016\/j.ophtha.2008.10.016","journal-title":"Ophthalmology"},{"key":"5169_CR3","doi-asserted-by":"crossref","unstructured":"Antcliff RJ, Marshall J (1999) The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol 14(4):223\u2013232","DOI":"10.3109\/08820539909069541"},{"key":"5169_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.survophthal.2008.10.001","volume":"54","author":"N Bhagat","year":"2009","unstructured":"Bhagat N, Grigorian RA, Tutela A, Zarbin MA (2009) Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol 54:1\u201332","journal-title":"Surv Ophthalmol"},{"key":"5169_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.5301\/EJO.2010.6050","volume":"21","author":"S Scholl","year":"2011","unstructured":"Scholl S, Augustin A, Loewenstein A, Rizzo S, Kuppermann BD (2011) General pathophysiology of macular edema. Eur J Ophthalmol 21:10\u201319","journal-title":"Eur J Ophthalmol"},{"key":"5169_CR6","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s00417-010-1315-z","volume":"248","author":"BP Nicholson","year":"2010","unstructured":"Nicholson BP, Schachat AP (2010) A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 248:915\u2013930","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5169_CR7","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/eye.2013.107","volume":"27","author":"KG Falavarjani","year":"2013","unstructured":"Falavarjani KG, Nguyen Q (2013) Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye 27:787\u2013794","journal-title":"Eye"},{"key":"5169_CR8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ophtha.2008.09.037","volume":"116","author":"H Funatsu","year":"2009","unstructured":"Funatsu H, Noma H, Mimura T, Eguchi S, Hori S (2009) Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology 116:73\u201379","journal-title":"Ophthalmology"},{"key":"5169_CR9","doi-asserted-by":"publisher","first-page":"5906","DOI":"10.1167\/iovs.12-10410","volume":"53","author":"SD Schoenberger","year":"2012","unstructured":"Schoenberger SD, Kim SJ, Sheng J, Rezaei KA, Lalezary M, Cherney E (2012) Increased prostaglandin E2 (PGE2) levels in proliferative diabetic retinopathy, and correlation with VEGF and inflammatory cytokines. Invest Ophthalmol Vis Sci 53:5906\u20135911","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"5169_CR10","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3109\/02713683.2012.661114","volume":"37","author":"J Zhou","year":"2012","unstructured":"Zhou J, Wang S, Xia X (2012) Role of intravitreal inflammatory cytokines and angiogenic factors in proliferative diabetic retinopathy. Curr Eye Res 37:416\u2013420","journal-title":"Curr Eye Res"},{"key":"5169_CR11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.survophthal.2009.07.005","volume":"55","author":"SJ Kim","year":"2010","unstructured":"Kim SJ, Flach AJ, Jampol LM (2010) Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol 55:108\u2013133","journal-title":"Surv Ophthalmol"},{"key":"5169_CR12","first-page":"689","volume":"2","author":"D Callanan","year":"2008","unstructured":"Callanan D, Williams P (2008) Topical nepafenac in the treatment of diabetic macular edema. ClinOphthalmol (Auckland, NZ) 2:689","journal-title":"ClinOphthalmol (Auckland, NZ)"},{"key":"5169_CR13","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1097\/IAE.0000000000000403","volume":"35","author":"SM Friedman","year":"2015","unstructured":"Friedman SM, Almukhtar TH, Baker CW, Glassman AR, Elman MJ, Bressler NM, Maker MP, Jampol LM, Melia M, Network DRCR (2015) Topical nepafenec in eyes with non-central diabetic macular edema. Retina (Philadelphia, Pa) 35:944","journal-title":"Retina (Philadelphia, Pa)"},{"key":"5169_CR14","doi-asserted-by":"publisher","first-page":"768","DOI":"10.3109\/02713683.2011.585734","volume":"36","author":"RM Maldonado","year":"2011","unstructured":"Maldonado RM, Vianna RN, Cardoso GP, de Magalh\u00e3es AV, Burnier MN Jr (2011) Intravitreal injection of commercially available ketorolac tromethamine in eyes with diabetic macular edema refractory to laser photocoagulation. Curr Eye Res 36:768\u2013773","journal-title":"Curr Eye Res"},{"key":"5169_CR15","doi-asserted-by":"publisher","first-page":"326","DOI":"10.5301\/ejo.5000888","volume":"27","author":"A Pinna","year":"2017","unstructured":"Pinna A, Blasetti F, Ricci GDA, Boscia F (2017) Bromfenac eyedrops in the treatment of diabetic macular edema: a pilot study. Eur J Ophthalmol 27:326\u2013330","journal-title":"Eur J Ophthalmol"},{"key":"5169_CR16","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s10792-014-9967-z","volume":"35","author":"M Soheilian","year":"2015","unstructured":"Soheilian M, Karimi S, Ramezani A, Montahai T, Yaseri M, Soheilian R, Peyman GA (2015) Intravitreal diclofenac versus intravitreal bevacizumab in naive diabetic macular edema: a randomized double-masked clinical trial. Int Ophthalmol 35:421\u2013428","journal-title":"Int Ophthalmol"},{"key":"5169_CR17","doi-asserted-by":"publisher","unstructured":"Sahoo S, Barua A, Myint KT, Haq A, Abas AB, Nair NS (2015) Topical non\u2010steroidal anti\u2010inflammatory agents for diabetic cystoid macular oedema. Cochrane Database Syst Rev (2):CD010009. https:\/\/doi.org\/10.1002\/14651858.CD010009.pub2","DOI":"10.1002\/14651858.CD010009.pub2"},{"key":"5169_CR18","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1001\/jamaophthalmol.2013.5692","volume":"132","author":"SD Schoenberger","year":"2014","unstructured":"Schoenberger SD, Kim SJ, Sheng J, Calcutt MW (2014) Reduction of vitreous prostaglandin E2 levels after topical administration of ketorolac 0.45%. JAMA Ophthalmol 132:150\u2013154","journal-title":"JAMA Ophthalmol"},{"key":"5169_CR19","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ajo.2016.09.012","volume":"172","author":"VH Gonzalez","year":"2016","unstructured":"Gonzalez VH, Campbell J, Holekamp NM, Kiss S, Loewenstein A, Augustin AJ, Ma J, Ho AC, Patel V, Whitcup SM (2016) Early and long-term responses to anti\u2013vascular endothelial growth factor therapy in diabetic macular edema: analysis of protocol I data. Am J Ophthalmol 172:72\u201379","journal-title":"Am J Ophthalmol"},{"key":"5169_CR20","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","volume":"372","author":"JA Wells","year":"2015","unstructured":"Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ (2015) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372:1193\u20131203","journal-title":"N Engl J Med"},{"key":"5169_CR21","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.exer.2015.10.009","volume":"145","author":"JE Chastain","year":"2016","unstructured":"Chastain JE, Sanders ME, Curtis MA, Chemuturi NV, Gadd ME, Kapin MA, Markwardt KL, Dahlin DC (2016) Distribution of topical ocular nepafenac and its active metabolite amfenac to the posterior segment of the eye. Exp Eye Res 145:58\u201367","journal-title":"Exp Eye Res"},{"key":"5169_CR22","first-page":"367","volume":"1","author":"HP Sandoval","year":"2007","unstructured":"Sandoval HP, de Castro LEF, Vroman DT, Solomon KD (2007) A review of the use of ketorolac tromethamine 0.4% in the treatment of post-surgical inflammation following cataract and refractive surgery. ClinOphthalmol (Auckland, NZ) 1:367","journal-title":"ClinOphthalmol (Auckland, NZ)"},{"key":"5169_CR23","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/eye.2011.296","volume":"26","author":"T Yilmaz","year":"2012","unstructured":"Yilmaz T, Cordero-Coma M, Gallagher M (2012) Ketorolac therapy for the prevention of acute pseudophakic cystoid macular edema: a systematic review. Eye 26:252","journal-title":"Eye"},{"key":"5169_CR24","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1097\/IAE.0b013e3181b094e6","volume":"29","author":"JS Heier","year":"2009","unstructured":"Heier JS, Awh CC, Busbee BG, Waterbury LD, Daniel P, Stoller GL, Cleary TS (2009) Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%. Retina 29:1310\u20131313","journal-title":"Retina"},{"key":"5169_CR25","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1001\/jamaophthalmol.2013.6203","volume":"132","author":"SD Schoenberger","year":"2014","unstructured":"Schoenberger SD, Kim SJ, Shah R, Sheng J, Cherney E (2014) Reduction of interleukin 8 and platelet-derived growth factor levels by topical ketorolac, 0.45%, in patients with diabetic retinopathy. JAMA Ophthalmol 132:32\u201337","journal-title":"JAMA Ophthalmol"},{"key":"5169_CR26","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1001\/archophthalmol.2012.393","volume":"130","author":"R Rajendram","year":"2012","unstructured":"Rajendram R, Fraser-Bell S, Kaines A, Michaelides M, Hamilton RD, Degli Esposti S, Peto T, Egan C, Bunce C, Leslie RD (2012) A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 130:972\u2013979","journal-title":"Arch Ophthalmol"},{"key":"5169_CR27","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.ophtha.2006.12.028","volume":"114","author":"JF Arevalo","year":"2007","unstructured":"Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, Sanchez JG, Wu L, Maia M, Berrocal MH, Solis-Vivanco A, Farah ME, Group P-ACRS (2007) Primary intravitrealbevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 114:743\u2013750","journal-title":"Ophthalmology"},{"key":"5169_CR28","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.oret.2017.09.010","volume":"2","author":"MHJ Bonyadi","year":"2018","unstructured":"Bonyadi MHJ, Baghi A, Ramezani A, Yaseri M, Soheilian M (2018) One-year results of a trial comparing 2 doses of intravitreal ziv-aflibercept versus bevacizumab for treatment of diabetic macular edema. Ophthalmol Retina 2:428\u2013440","journal-title":"Ophthalmol Retina"},{"key":"5169_CR29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00417-010-1452-4","volume":"249","author":"S Goyal","year":"2011","unstructured":"Goyal S, LaValley M, Subramanian ML (2011) Meta-analysis and review on the effect of bevacizumab in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 249:15\u201327","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5169_CR30","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1001\/jamaophthalmol.2019.1963","volume":"137","author":"NM Bressler","year":"2019","unstructured":"Bressler NM, Odia I, Maguire M, Glassman AR, Jampol LM, MacCumber MW, Shah C, Rosberger D, Sun JK (2019) Association between change in visual acuity and change in central subfield thickness during treatment of diabetic macular edema in participants randomized to aflibercept, bevacizumab, or ranibizumab: a post hoc analysis of the Protocol T Randomized Clinical Trial. JAMA Ophthalmol 137:977\u2013985","journal-title":"JAMA Ophthalmol"},{"key":"5169_CR31","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/jamaophthalmol.2018.6786","volume":"137","author":"SB Bressler","year":"2019","unstructured":"Bressler SB, Odia I, Maguire MG, Dhoot DS, Glassman AR, Jampol LM, Marcus DM, Solomon SD, Sun JK (2019) Factors associated with visual acuity and central subfield thickness changes when treating diabetic macular edema with anti\u2013vascular endothelial growth factor therapy: an exploratory analysis of the protocol T randomized clinical trial. JAMA Ophthalmol 137:382\u2013389","journal-title":"JAMA Ophthalmol"},{"key":"5169_CR32","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.ophtha.2006.06.052","volume":"114","author":"DRCR Network","year":"2007","unstructured":"Network DRCR (2007) Relationship between optical coherence tomography\u2013measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmol 114:525\u2013536","journal-title":"Ophthalmol"},{"key":"5169_CR33","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/eye.2014.182","volume":"28","author":"E Hatef","year":"2014","unstructured":"Hatef E, Hanout M, Moradi A, Colantuoni E, Bittencourt M, Liu H, Sepah Y, Ibrahim M, Do D, Guyton DL (2014) Longitudinal comparison of visual acuity as measured by the ETDRS chart and by the potential acuity meter in eyes with macular edema, and its relationship with retinal thickness and sensitivity. Eye 28:1239\u20131245","journal-title":"Eye"},{"key":"5169_CR34","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1136\/bjophthalmol-2013-303417","volume":"97","author":"A Russo","year":"2013","unstructured":"Russo A, Costagliola C, Delcassi L, Romano MR, Semeraro F (2013) A randomised controlled trial of ranibizumab with and without ketorolac eyedrops for exudative age-related macular degeneration. Br J Ophthalmol 97:1273\u20131276","journal-title":"Br J Ophthalmol"},{"key":"5169_CR35","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1097\/IAE.0000000000000525","volume":"35","author":"F Semeraro","year":"2015","unstructured":"Semeraro F, Russo A, Delcassi L, Romano MR, Rinaldi M, Chiosi F, Costagliola C (2015) Treatment of exudative age-related macular degeneration with ranibizumab combined with ketorolac eyedrops or photodynamic therapy. Retina 35:1547\u20131554","journal-title":"Retina"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-021-05169-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-021-05169-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-021-05169-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T08:28:47Z","timestamp":1632817727000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-021-05169-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,15]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["5169"],"URL":"https:\/\/doi.org\/10.1007\/s00417-021-05169-1","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,15]]},"assertion":[{"value":"22 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures in this study were approved by the Ethics Committee of the Ophthalmic Research Center at Shahid Beheshti University of Medical Sciences, Tehran, Iran. Written informed consent was obtained from each participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}